Brigatinib: First Global Approval

2018-04-10T02:55:18Z (GMT) by Anthony Markham
Compliance with Ethical Standards

Funding: The preparation of this review was not supported by any external funding.

Conflict of Interest: A. Markham is a contracted employee of Adis, Springer SBM.

Additional information about this Adis Drug Review can be found here.

Abstract

Brigatinib (Alunbrig™) is a small molecule antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals. In April 2017 brigatinib was approved in the USA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. The development of resistance to the latter is a therapeutic challenge which has led to the development of second-generation ALK-inhibitors such as brigatinib which have activity against treatment-resistant ALK mutants. This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib. Access to the full article can be found here.

© Springer International Publishing AG, part of Springer Nature 2017